The American Society for Pharmacy Law (ASPL) is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties.

ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: 

  • Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues;
  • Communicating accurate legal educational information; and
  • Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law

Latest News

May 5, 2025

FDA Reiterates That Discretion for Pharmacies Compounding Semaglutide Has Expired

The Food and Drug Administration reiterated that it can now take action against pharmacies compounding, distributing, or dispensing semaglutide injection products that are essentially a copy of an FDA-approved product. This follows a Texas judge recently denying an injunction from the Outsourcing Facilities Association in the case Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.). The FDA had originally granted discretion to pharmacies compounding semaglutide until April 22, 2025.

For outsourcing facilities compounding, distributing, or dispensing semaglutide injection products under section 503B, the FDA does not intend to take action for violations of the Federal Food, Drug, and Cosmetic Act arising from conditions that depend on semaglutide injection products’ inclusion on the FDA’s drug shortage list until May 22, 2025.

The FDA stated that it may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe.

[FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA 28 Apr 2025.]